Abstract: The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and/or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.
| # | Name | Date |
|---|---|---|
| 1 | 202317047252-STATEMENT OF UNDERTAKING (FORM 3) [13-07-2023(online)].pdf | 2023-07-13 |
| 2 | 202317047252-Sequence Listing in txt [13-07-2023(online)].txt | 2023-07-13 |
| 3 | 202317047252-Sequence Listing in PDF [13-07-2023(online)].pdf | 2023-07-13 |
| 4 | 202317047252-REQUEST FOR EXAMINATION (FORM-18) [13-07-2023(online)].pdf | 2023-07-13 |
| 5 | 202317047252-POWER OF AUTHORITY [13-07-2023(online)].pdf | 2023-07-13 |
| 6 | 202317047252-FORM 18 [13-07-2023(online)].pdf | 2023-07-13 |
| 7 | 202317047252-FORM 1 [13-07-2023(online)].pdf | 2023-07-13 |
| 8 | 202317047252-DECLARATION OF INVENTORSHIP (FORM 5) [13-07-2023(online)].pdf | 2023-07-13 |
| 9 | 202317047252-COMPLETE SPECIFICATION [13-07-2023(online)].pdf | 2023-07-13 |
| 10 | 202317047252-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [13-07-2023(online)].pdf | 2023-07-13 |
| 11 | 202317047252-Proof of Right [19-09-2023(online)].pdf | 2023-09-19 |
| 12 | 202317047252-FORM-26 [19-09-2023(online)].pdf | 2023-09-19 |
| 13 | 202317047252-FORM 3 [29-11-2023(online)].pdf | 2023-11-29 |